-- Eisai (TYO:4523) said global revenue for Alzheimer's treatment Leqembi reached 88 billion yen on a preliminary basis for the year ended March, according to a Thursday filing on the Tokyo Stock Exchange.
The U.S. accounted for 44.6 billion yen of sales, followed by Japan at 24.4 billion yen and China at 12.4 billion yen.